Clinical Trial Update: Phase I Trial of CC-8490 for the Treatment of Subjects With Recurrent/Refractory High-Grade Gliomas [Phase 1]

View source ↗

Summary

Phase I trial of CC-8490 for recurrent/refractory high-grade gliomas, including glioblastoma and malignant gliomas, has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Glioblastoma
• Malignant Gliomas

Drugs mentioned

• CC-8490

Snippet

Sponsor: Celgene Corporation | Conditions: Glioblastoma, Malignant Gliomas | Phase 1 | Status: COMPLETED